TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05569902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tACS
Description: transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: transcranial alternating current stimulation is a non-invasive method of entraining specific frequency bands in the brain by applying weak intensities of electric current in a desired shape and phase to the desired brain regions.
Study: NCT03947190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge
Description: PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
Study: NCT04905550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 110mg p.o qd. Treatment with Almonertinib will continue until progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
Description: Image guided, 24-15 Gy\*1F was recommended if use SRS. 9-12 Gy\*3F/1W or 6Gy×5F/1W was recommended if use SRT. 30Gy/10F/2W for WBRT, large residual lesions will be treated with a local dose (≤DT 45Gy/15F).
Study: NCT06435208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subgingival instrumentation
Description: All the participants will undergo scaling and root planning with hand scalers, curettes and ultrasonic scaler.
Study: NCT06021925

Intervention type: OTHER
Intervention: Obstetrical history
Description: Selection of donors by EFS retrospectively on the basis of inclusion criteria. Information note sent by e-mail, non-opposition as well as a questionnaire to be completed online to obtain data on obstetrical history.

Intervention type: OTHER
Intervention: Anti-HLA Antibody tests
Description: Analyze responses in relation to the results of the anti-HLA Antibody tests performed at the time of donation.
Study: NCT06235866

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: According to the pulmonary rehabilitation guidelines, patients with severe COVID-19 were given regular rehabilitation treatment, including breathing exercises and physical rehabilitation exercises.
Study: NCT05182723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: renal replacement therapy
Description: Extracorporeal Methods for Removing Mediators of Systemic Inflammation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal replacement therapy
Description: Extracorporeal Methods for Removing Mediators of Systemic Inflammation
Study: NCT05579015

Intervention type: DEVICE
Group type: OTHER
Intervention: Theta-burst stimulation (TBS)
Description: TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: TBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz), as described previously. iTBS consists of 2-second trains with an inter-train interval of 8 seconds. The investigators will repeat the trains (30 pulses; 10 bursts) 20 times to reach a total number of 600 pulses (3x10x20). cTBS will comprise uninterrupted bursts to reach a total of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT). This corresponds to \~110% of the active motor threshold. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimize dropout rates. Still, scalp discomfort will be recorded directly after the stimulation. The stimulation site over the DLPFC will be determined using the international 10-20 system and correspond to the F3 label.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone interviews
Description: Telephone interviews will be conducted at the follow-up stage. RMDD group will receive follow-up telephone interviews every 3 months for 2 years to monitor major depressive episode recurrence
Study: NCT05709860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMC2 PrEP Educational Tool
Description: Patients will receive an interactive PrEP Educational Tool. This interactive tool will be securely sent via the patient portal. After logging into their portal, patients will have the opportunity to review the information on their own time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discrete Scheduling of a Dedicated PrEP Visit
Description: Within the interactive PrEP Educational Tool, patients who choose to will have the opportunity to discretely schedule a dedicated PrEP visit with a primary care clinician trained on PrEP delivery. The clinician will have time reserved to allow for 'rapid' scheduling.
Study: NCT05983419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Complete resection of Barrett's esophagus harboring neoplasia with endoscopic submucosal dissection.
Study: NCT04992572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 25mg Propofol administered by injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride, Injectable
Description: Licocaine administered locally via injection.
Study: NCT05904561

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: comparing between the effect of low level laser therapy (LLLT) and pulsed ultrasound on post-partum carpal tunnel syndrome. All interventions that were pre-specified to be administered as part of the protocol, even if a particular intervention is not of interest
Study: NCT05619029

Intervention type: RADIATION
Intervention: X-ray
Description: Chest radiographs

Intervention type: RADIATION
Intervention: X-ray
Description: Chest radiographs
Study: NCT05644314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The drug-eluting stent
Description: Vertebral artery drug-eluting stents Maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials.
Study: NCT06327698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib
Description: capsule
Study: NCT05408962

Intervention type: OTHER
Intervention: Blood and urine collection, anthropometric analysis and answering to questionnaires
Description: During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.

Intervention type: OTHER
Intervention: Blood and urine collection, anthropometric analysis and answering to questionnaires
Description: During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.

Intervention type: OTHER
Intervention: Blood and urine collection, anthropometric analysis and answering to questionnaires
Description: During the visit to the recruitment center, participants will sign an informed consent. They will have to be in fasting condition for blood and urine collection. In addition they will answer the lifestyle questionnaire and the Food Frequency Questionnaire and will be submitted to an anthropometric analysis and evaluation of blood preassure and heart rate.
Study: NCT04921566

Intervention type: DRUG
Group type: OTHER
Intervention: Torasemide tablet 10 mg
Description: Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.

Intervention type: DRUG
Group type: OTHER
Intervention: Torasemide tablet 10 mg
Description: Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.

Intervention type: DRUG
Group type: OTHER
Intervention: Toradiur® tablet 10 mg
Description: Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.

Intervention type: DRUG
Group type: OTHER
Intervention: Toradiur® tablet 10 mg
Description: Toradiur® is manufactured by MEDA Manufacturing Cologne, Germany. Each tablet contains 10 mg of torasemide.
Study: NCT05532865

Intervention type: OTHER
Intervention: Blood samples
Description: 80 ml of blood samples collected at inclusion and at 18 months

Intervention type: OTHER
Intervention: Stool samples
Description: A stool sample for collection of digestive microbiota at inclusion

Intervention type: OTHER
Intervention: Skin swab samples
Description: A skin swab sample for collection of skin microbiota at inclusion and at 18 months

Intervention type: OTHER
Intervention: Questionnaires on quality of life, pain and disability
Description: At inclusion and each year for 5 years

Intervention type: OTHER
Intervention: Skin biopsies
Description: At inclusion and 18 months
Study: NCT06151548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THYROX (Atlantic krill oil).
Description: The daily content of krill oil is 2000 mg, including omega-3 fatty acids 350 mg, EPA - 240 mg, DHA - 110 mg, phospholipids - 800 mg, astaxanthin 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The control capsules will be made of olive oil of equal size and color.
Study: NCT05582486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: obstetric violence prevention education intervention
Description: While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: obstetric violence prevention education intervention
Description: While the training program for the prevention of obstetric violence consisting of 16 sessions was applied by the researcher to the midwives and nurses in the experimental group, no intervention was applied to the midwives and nurses in the control group.
Study: NCT04498078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine monohydrate (20 g per day)
Study: NCT05361369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule
Description: Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
Study: NCT05255146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atricure Inc. Nitrous oxide Cryoprobe
Description: Cryoanalgesia will be given by applying a nitrous oxide-cooled probe (AtriCure, Inc. 2000) locally to intercostal nerves in the 4th, 5th, and 6th rib spaces after completion of the surgical repair and before surgical closure. The probe will be cooled to -60°C and held on each location for 60 sec.
Study: NCT05574491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Skills for Life: traditional version
Description: Structured and manualized intervention with a manual for the therapist and a workbook for the children.~The intervention will be administered by trained clinical psychologists in SSL. Sessions will be held once a week for eight weeks, with each session lasting approximately forty five minutes.~The program includes emotional education, social skills training, cognitive restructuring, relaxation techniques, self-observation, problem solving and behavioural activation. These contents are learned through playful exercises, activities, readings, and role-playing.~Both modalities of intervention will be in-person.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Skills for Life: computerized version
Description: Structured and manualized intervention with a manual for the therapist and multimedia material for the children.
Study: NCT06218563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration-induced illusion of movement
Description: Conditions order is pseudorandomized, participants can start by the left or the right arm with eyes opened or closed. When starting with either the left or right arm, all conditions are completed before moving on to the other arm (for healthy participants). In total, the number of participants starting with right or left vibration should be the same.
Study: NCT06133322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
Description: The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Evidence-based interventions recommended by the 2017 ACC/AHA hypertension clinical guideline
Description: The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension
Study: NCT05599308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMRON blood pressure monitor with AFib screening feature
Description: Blood pressure measurement by an oscillometric blood pressure monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMRON blood pressure monitor with AFib screening feature
Description: Blood pressure measurement by an oscillometric blood pressure monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microlife WatchBP Home A
Description: Blood pressure measurement by an oscillometric blood pressure monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microlife WatchBP Home A
Description: Blood pressure measurement by an oscillometric blood pressure monitor
Study: NCT04752267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FMAU
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05697783

Intervention type: DRUG
Intervention: Administration of methadone instead of fentanyl patch
Description: comparison of delirium rates in methadone vs fentanyl patch treated patients
Study: NCT05308992

Intervention type: DEVICE
Group type: OTHER
Intervention: HydroGlyde Condom
Description: The latex HydroGlyde condom has a hydrophilic coating which maintains its lubricity when in contact with water. Improved lubrication during intercourse may lead to improved user satisfaction and increased condom use which would help prevent the spread of Sexually Transmitted Infections and unwanted pregnancies.
Study: NCT05529108

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control biscuits
Description: Consumption of plain biscuits everyday during intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: autoclaved BSG-containing biscuits
Description: Consumption of autoclaved BSG-containing biscuits everyday during intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bio-transformed BSG-containing biscuits
Description: Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
Study: NCT05327179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Treatment
Description: Action Observation Treatment program will be applied to the group 1 for 3 weeks, 5 days a week, 30 minutes a day. In the videos prepared, activities including daily life activities for the wrist, elbow and shoulder (emptying water from the glass, throwing sugar into the glass, painting, using clothespins, spoons, etc.) will be included.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Rehabilitation
Description: Virtual Rehabilitation program will be applied to the group 2 for 3 weeks, 5 days a week, 30 minutes a day. Among the games, games that will improve daily life activities for the wrist, elbow and shoulder (steering wheel, popping balloons, touching the aquarium, etc.) will be selected.
Study: NCT05478941

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Progressive Muscular Relaxation via Zoom, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).
Description: * Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Progressive Muscular Relaxation via Audio-track, and Exposure to a Virtual Reality scenarios deployed by an Head mounted tool (Oculus Quest 2).
Description: * Four individual PMRT sessions via Audio-track.~* In vivo PMRT relaxing session and Virtual Reality exposure (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the virtual reality scenario based on an in-imagination session, and the PMRT session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscular Relaxation via Zoom, and Exposure to a Guided Imagery Exposure.
Description: * Four individual PMRT sessions via Zoom.~* In vivo PMRT relaxing session and Guided Imagery conducted by the Psychotherapist (T1; day 7).~* Follow-up phase (T2; day 14), after two weeks. Recovering the in-imagination relaxing scenario and PMRT session.
Study: NCT06330740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Upon ordering antibiotics the provider will be prompted to utilize an indication-based order set which guides the clinician to the appropriate empiric antibiotic choice.
Study: NCT05228665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRV-B)
Description: Breathing technique twice every day (10 min each) to increase HRV
Study: NCT05947188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prostate cancer diagnosis
Description: prostate cancer diagnosis
Study: NCT05677893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBS-COV
Description: MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05714826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preop Intervention and Monitored Recovery
Description: Perioperative Optimization of Senior Health (POSH) Program; patient monitoring by device orientation, initial intake, education; ERAS protocol, inpatient geriatric co-management; and remote monitoring with Acticare device; post-op continuity of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: ERAS, Usual referral and recovery care, and Standard follow-up protocol
Study: NCT06543667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Limbal Stem Cell Derived Exosomes Eye Drop
Description: Patients will receive artificial tears for 2 weeks to get the normalized baseline, followed by LSC-Exo eye drops 0.15 ml/single eye/one time, four times a day for 3 months. The follow-up visit will be 12 weeks since the administration of LSC-Exo eye drops.
Study: NCT06276998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsule; Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule; Oral
Study: NCT05128461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: M-CIMT-based telerehabilitation will be implemented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program
Description: Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program
Description: Lower and upper extremity exercises and gait training exercises selected according to the Bobath approach will be given as a home program consisting of 10 same exercises.
Study: NCT04763395

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05892614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efzofitimod 450 mg
Description: IV infusion over approximately 60 minutes every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efzofitimod 270 mg
Description: IV infusion over approximately 60 minutes every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion over approximately 60 minutes every 4 weeks